Does rhamnetin induce sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents?
Together, our findings suggest that rhamnetin treatment may attenuate the MDR process in HCC cells. These findings may contribute to more effective strategies for HCC therapy.
Acute neurological deficits may occur in TTP without concurrent thrombocytopenia or microangiopathic hemolysis. The role of rituximab for patients with TTP deserves further exploration.